Diakonhjemmet Hospital
Nina Sundlisæter
The goal of this multi-center prospective observational study is to develop knowledge on how to best personalize treatment and follow-up strategies for patients with RA in remission, with the intention to prevent relapse of disease activity and progression of joint damage and at the same time avoid the use of unnecessary treatment and health resources. The investigators will perform an extensive evaluation of all patients who participated in the ARCTIC REWIND study 10 and 15 years after they achieved sustained remission and received different treatment strategies.
Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects 0.5 to 1.0% of the population. In case of ineffective treatment, the inflammation can lead to joint destruction and reduced physical function, as well as affecting internal organs. RA is associated with an increased risk of cardiovascular disease and osteoporosis. The prognosis for RA has improved significantly over the past two decades, with effective treatment strategies and available drugs allowing a significant proportion of patients to achieve the treatment goal of remission (absence of signs of inflammation). RA has thus become a 'controllable' disease, and the large increase in the number of RA patients in remission leaves a need for improved understanding of how to best treat these patients. A total of 259 RA patients in sustained remission were included in the ARCTIC REWIND trial. They were randomized to either tapering of DMARDs, or to continue stable DMARD medication, and followed for three years. The current study will provide a 10- and 15-year follow-up on the outcome of all these patients. The results from the project will add knowledge about the long-term consequences of achieving sustained remission, as well as of experiencing a disease activity flare regarding DMARD use, joint damage progression, functional status and work productivity, and the study will provide novel data on cardiovascular health and other comorbidities in this patient group. Further, the patient perspective on flare will be explored. Such information will be valuable for patients and clinicians to improve shared decision on further treatment, and potentially allow more patients to reduce treatments in an evidence-based manner. Results from the study could influence approaches to the management of RA in the future, as selecting patients who can be switched to remote care (reduce the number of visits the patient has to attend physically).
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 259 participants |
| Official Title : | The ARCTIC REWIND Extension Study - Long-term Outcomes of Patients with Rheumatoid Arthritis in Remission |
| Actual Study Start Date : | 2025-11 |
| Estimated Primary Completion Date : | 2034-01 |
| Estimated Study Completion Date : | 2034-01 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Haukeland University Hospital
Bergen, Norway,
Not yet recruiting
Vestre Viken Hospital
Drama, Norway,
Not yet recruiting
Sørlandet Hospital
Kristiansand, Norway,
Not yet recruiting
Rheumatism hospital
Lillehammer, Norway,
Not yet recruiting
Helgeland Hospital Mo i Rana
Mo i Rana, Norway,
Not yet recruiting
Østfold Hospital
Moss, Norway,
Not yet recruiting
Diakonhjemmet Hospital
Oslo, Norway,
Not yet recruiting
Martina Hansens Hospital
Sandvika, Norway,
Not yet recruiting
University Hospital of North Norway
Tromsø, Norway,
Not yet recruiting
Ålesund Hospital
Ålesund, Norway,